SecBot SecBot
Insider Cluster (3 insiders) ·Filed Jul 9, 2026

IMNM

Immunome Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago
Insider cluster: 3 insiders, $0.8M total
Actionable Insight • Neutral

The sales are too small relative to market cap to warrant a bearish stance. Monitor for any unplanned insider sales in the next 30 days; if a pattern of C-suite selling continues above 0.5% of market cap, that would be a more credible signal. For now, the cluster reads as routine diversification.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.35
T+0 close · Jul 9, 2026 · via day close
Latest settled
−9.34%
T+60 · $21.17
Vs SPY
−11.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $23.35entry
  2. T+1 · 4mo ago −2.36%α −1.59% · $22.80
  3. T+5 · 4mo ago −4.93%α −4.36% · $22.20
  4. T+20 · 3mo ago +7.19%α +4.77% · $25.03
  5. T+60 · 6w ago −9.34%α −11.97% · $21.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three Immunome insiders sold a total of ~$813K in open-market shares over a one-week window ending July 7, 2026, including the Chief Business Officer, the Chief Medical Officer, and a Director. Director Barchas Isaac alone sold ~$2.4M across two days (July 6–7), making this the dominant insider transaction. At ~0.03% of Immunome's $2.7B market cap, the total sales are trivial in proportional terms, and cluster sales are weak directional signals per the academic literature. The sales are best interpreted as routine portfolio diversification, not a bearish corporate signal.

Key Financial Metrics

Direction
selling
Total Value
$2.8M
Insiders
3

Key Facts

  • Three insiders sold shares: Director Isaac Barchas ($2.4M), CBO Horn Kinney ($27K + option exercise), CMO Robert Lechleider ($377K)
  • Total open-market sales: ~$2.84M; total cluster value after netting derivative exercises: ~$813K
  • Sales represent ~0.1% of Immunome's $2.7B market cap
  • No insider purchases were filed in this cluster window

Financial Impact

$2.84M in total insider open-market sales, or ~0.1% of market cap

insider ownershipfloat

Risk Factors

  • Additional insider selling in coming weeks could signal deteriorating conviction

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IMNM-1783634473409

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026